Industry News Merck Endpoints News
Merck stops nemtabrutinib, the BTK inhibitor behind its $2.7B ArQule deal
- Merck has ended development of nemtabrutinib (MK-1026), the main reason it bought ArQule for $2.7 billion in 2019.
- The drug was in a slew of trials in blood cancers; Fierce Biotech's headline ties the decision to Phase 3 data.
- Merck had earlier booked a write-down on the asset.
This closes the book on one of Merck's weaker acquisitions: a non-covalent BTK inhibitor was meant to answer resistance to covalent drugs, but BTK degraders and strong incumbents narrowed the opening. For Merck, the loss is mostly sunk cost; the more telling point is how little the ArQule price bought beyond this molecule. Competitors in the non-covalent class, like Lilly's pirtobrutinib, face one fewer rival.
Source: Endpoints News ↗ Merck ends the sorry saga of BTK inhibitor it got from ArQule